Below is a list of grant and award recipients. You may narrow the list down by using the filters below. The list can be sorted by year, last name, and institution. The institution listed reflects the sponsoring institution at the time of grant or award.
Past Recipients Year First Name Last Name Degree Institution Title Subject Area
2019 Zaid Abdel Rahman MD Mayo Clinic Evaluation of etiologic genetic polymorphisms by whole exome sequencing (WES) in the Mayo Clinic AML epidemiology cohort (MCAEC).
2019 Jithma Abeykoon MD Mayo Clinic Outcomes with rituximab plus bendamustine (R-Benda), dexamethasone, rituximab, cyclophosphamide (DRC), and bortezomib, dexamethasone, rituximab (BDR) as primary therapy in patients with Waldenstrom macroglobulinemia (WM).
2019 Iman Aboudalle MD The University of Texas M.D. Anderson Cancer Center Impact of luteinizing hormone suppression on hematopoietic recovery after intensive chemotherapy in patients with leukemia.
2019 Nour Abuhadra MD The University of Texas M.D. Anderson Cancer Center Beyond TILs: Predictors of pathologic complete response (pCR) in triple-negative breast cancer (TNBC) patients with moderate tumor-infiltrating lymphocytes (TIL) receiving neoadjuvant therapy.
2019 Mihaela Aldea MD, PhD Gustave Roussy Circulating tumor DNA analysis (ctDNA) for genomic testing in NSCLC patients with isolated CNS progression.
2019 Mansour Alfayez MD, MS The University of Texas M.D. Anderson Cancer Center Smoking is associated with poor risk ELN 2017, cytogenetics/molecular profile, and confers poor survival outcomes in acute myeloid leukemia.
2019 Kartik Anand MBBS Houston Methodist Cancer Center Comprehensive report of anti-CD19 chimeric antigen receptor T cells (CAR-T) associated non-relapse mortality (CART-NRM) from FAERS.
2019 Avani Athauda MBBS The Royal Marsden Hospital Impact of age and sex on chemotherapy (CTx) efficacy, toxicity and survival in early oesophagogastric (OG) cancer: A pooled analysis of 3265 patients from four large randomised trials (OE02, OE05, MAGIC & ST03).
2019 Florence Atrafi MD, MSc Maastricht University A phase I dose-finding and pharmacokinetics study of CPC634 (nanoparticle entrapped docetaxel) in patients with advanced solid tumors.
2019 Dilip Babu MD University of Rochester Associations of uncertainty with psychological status and quality of life (QoL) among 527 older patients with advanced cancer.
2019 Marco Bandini MD Vita-Salute San Raffaele University Squamous-cell carcinoma variant histology (SCC-VH) in muscle-invasive bladder cancer (MIBC): A comprehensive clinical, genomic, and therapeutic assessment from multiple datasets.
2019 Francesca Battaglin MD University of Southern California Polymorphisms in the dopamine (DA) signaling to predict outcome in patients (pts) with metastatic colorectal cancer (mCRC): Data from TRIBE, MAVERICC, and FIRE-3 phase III trials.
2019 Jacob Berchuck MD Dana-Farber Cancer Institute Disparities in lung cancer outcomes for veterans with comorbid mental disorders.
2019 David Bond MD The Ohio State University Second cancer incidence in CLL patients receiving BTK inhibitors.
2019 Sam Brondfield MD University of California, San Francisco Feasibility of implementing a resident oncology video curriculum.
2019 Maria Alessandra Calegari MD Oncologia Medica, Fondazione Policlinico Universitario “A. Gemelli”, IRCCS Chemotherapy rechallenge or reintroduction (CTr/r), regofenib (REG) and TAS-102 for metastatic pretreated colorectal cancer (mCRC) patients (pts): A propensity score analysis of treatment beyond second-line (PROSERpINA Study).
2019 Kamal Chamoun MD University Hospitals Seidman Cancer Center Insurance status and survival of multiple myeloma (MM) patients.
2019 Bhavana Chapman MD The University of Texas M.D. Anderson Cancer Center Outcomes after adjuvant radiotherapy in breast cancer patients with and without germline mutations: A large, single-institutional experience.
2019 Fo-Ping Chen PhD Sun Yat-sen University Development of a clinicomolecular risk stratification system for nonmetastatic nasopharyngeal carcinoma using Epstein–Barr virus DNA and TNM stage: A “Big data” analysis of 9,160 endemic cases.
2019 Kelly Chien MD, BS The University of Texas M.D. Anderson Cancer Center Patterns of leukemic transformation in patients with TP53-mutant myelodysplastic syndromes.
2019 Mudit Chowdhary MD Rush University Medical Center Does the addition of chemotherapy to neoadjuvant radiotherapy impact survival in high-risk extremity and trunk soft tissue sarcoma?
2019 Julie Collins MD, MPH National Cancer Institute Phase I trial of a modified vaccinia ankara (MVA) priming vaccine followed by a fowlpox virus (FPV) boosting vaccine modified to express brachyury and costimulatory molecules in advanced solid tumors.
2019 Vincenza Conteduca MD, PhD Dana-Farber Cancer Institute SLFN11 expression (exp) in castration-resistant prostate cancer (CRPC) patients (pts) predicts response to platinum-based chemotherapy (PLT).
2019 Colleen Cuthbert PhD University of Calgary Patient level factors associated with chronic opioid use in cancer patients.
2019 Antonio Di Meglio MD Institut Gustave Roussy Impact of overweight, obesity and post-treatment weight changes on occupational reintegration of breast cancer (BC) survivors.
2019 Brunella Di Stefano MD Fondazione Policlinico Universitario A. Gemelli-IRCCS-UOC Oncologia Medica Clinical, pathological and prognostic features of rare BRAF mutations (MTs) in metastatic colorectal cancer (mCRC): A bi-institutional retrospective analysis (REBUS study).
2019 Stephanie Dixon MD, BS St. Jude Children's Research Hospital Chronic health conditions (CHC) and late mortality in survivors of acute lymphoblastic leukemia (ALL) in the Childhood Cancer Survivor Study.
2019 Nazli Dizman MD City of Hope Infigratinib in upper tract urothelial carcinoma vs urothelial carcinoma of the bladder and association with comprehensive genomic profiling/cell-free DNA results.
2019 Narjust Duma MD Mayo Clinic Evaluating unconscious bias: Speaker introductions at an international oncology conference.
2019 Lawson Eng MD Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre Impact of health behavior change on health utility (HU) and financial toxicity in head and neck cancer (HNC) survivors.
2019 Kelly Faulk MD University of Colorado Assessment of enrollment characteristics for Children’s Oncology Group (COG) upfront therapeutic clinical trials 2004-2015.
2019 Roberto Ferrara MD Istituto Nazionale dei Tumori Fast-progression (FP), hyper-progression (HPD) and early deaths (ED) in advanced non-small cell lung cancer (NSCLC) patients (pts) upon PD-(L)-1 blockade (IO).
2019 Arlindo Ferreira MD, MSc Institut Gustave Roussy Differential impact of endocrine therapy (ET) and chemotherapy (CT) on quality of life (QoL) of 4,262 breast cancer (BC) survivors: A prospective patient-reported outcomes (PRO) analysis.
2019 Jason Frankel MD Virginia Mason Medical Center Contemporary trends in treatment for low-risk prostate cancer.
2019 Ehsan Ghorani MBBS University College London Cancer Institute Imbalance between early and late differentiated intra-tumour CD4 T cells is associated with mutational burden in non-small cell lung cancer.
2019 Smith Giri MBBS Yale School of Medicine Chromosome 1 abnormalities and clinical outcomes in multiple myeloma in the era of novel agents.
2019 Ashley Graul MD University of Pennsylvania Effect of patient education on palliative care knowledge and acceptability of outpatient palliative care service among gynecologic oncology patients.
2019 Robin Guo MD Memorial Sloan Kettering Cancer Center MET inhibitor resistance in patients with MET exon 14-altered lung cancers.
2019 Andrew Hahn MD University of Utah Genomic landscape of metastatic hormone sensitive prostate cancer (mHSPC) vs. metastatic castration-refractory prostate cancer (mCRPC) by circulating tumor DNA (ctDNA).
2019 Evan Hall MD, MPhil Stanford University Economic analysis of alternative pembrolizumab and nivolumab dosing strategies at an academic cancer center.
2019 Anis Hamid MBBS Dana-Farber Cancer Institute Genomic predictors of benefit of docetaxel (D) and next-generation hormonal therapy (NHT) in metastatic castration resistant prostate cancer (mCRPC).
2019 Ross Harrison MD The University of Texas M.D. Anderson Cancer Center Cost-effectiveness analysis of laparoscopic disease assessment in ovarian cancer.
2019 Caroline Hesko MD, MPH, BS University of Chicago Neurocognitive outcomes in adult survivors of neuroblastoma: A report from the Childhood Cancer Survivor Study.
2019 Evthokia Hobbs MD The University of Texas M.D. Anderson Cancer Center Tumor immune microenvironment (TiME) changes by multiplex IF staining in a pilot study of neoadjuvant talazoparib for early-stage breast cancer patients with a BRCA mutation.
2019 Joshua Horton MD Medical University of South Carolina Neoadjuvant presurgical PD-1 inhibition in oral cavity squamous cell carcinoma.
2019 Liang Huang MD, PhD Huazhong University of Science and Technology Efficacy and safety of CAR19/22 t-cell “cocktail” therapy in patients with refractory/relapsed b-cell non-Hodgkin lymphoma.
2019 Marco Iafolla MD Princess Margaret Cancer Centre Bespoke circulating tumor DNA (ctDNA) analysis as a predictive biomarker in solid tumor patients (pts) treated with single agent pembrolizumab (P).
2019 Vikram Jairam MD Yale University Emergency department visits for prescription and synthetic opioid overdoses among patients with cancer.
2019 Emre Koca MD Houston Methodist Hospital Open label, phase II trial of neoadjuvant TAK-228 plus tamoxifen in patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor type 2 (HER2)-negative breast cancer-ANETT.
2019 Igal Kushnir MD Ottawa Hospital Cancer Centre Active surveillance in metastatic renal cell carcinoma (mRCC): Results from the Canadian Kidney Cancer information system (CKCis).